Physician profile
Stephen Rotman
NPI 1346567385
$5,572.78
in general payments reported to CMS, 2019-2025
19 companies · $3,206 in 2025
The $3,206 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $891 · 2020: $162 · 2021: $403 · 2022: $392 · 2023: $59.68 · 2024: $459 · 2025: $3,206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,206 · Food and Beverage: $489 · Education: $30.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,206.00 |
| Food and Beverage | $488.69 |
| Education | $30.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Medical Systems Corporation | $3,206.00 | 2025 | Evis Exera II Small Intestinal Videoscope |
| Abbvie INC. | $765.11 | 2019-2024 | Linzess |
| Braintree Laboratories, INC. | $283.49 | 2019-2022 | |
| Pfizer INC. | $194.63 | 2019-2024 | |
| Gilead Sciences, INC. | $140.84 | 2019-2022 | |
| Madrigal Pharmaceuticals | $139.49 | 2024 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $132.31 | 2024 | |
| Janssen Biotech, INC. | $120.59 | 2024 | Tremfya |
| Allergan, INC. | $114.23 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $91.70 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.75 | 2021-2022 | |
| Ucb, INC. | $67.58 | 2019-2020 | |
| Boston Scientific Corporation | $57.24 | 2020 | |
| Celgene Corporation | $51.22 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $43.60 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $27.27 | 2022 | |
| Nestle Healthcare Nutrition INC. | $24.57 | 2022 | |
| Ardelyx, INC. | $20.80 | 2023 | Ibsrela |
| Olympus America INC. | $15.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Rotman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.